JamshidMaddahiMDFACC, FASNC
Cardiology • Los Angeles, CAInterventional Cardiology
Clinical Professor, Medicine (Cardiology) and Molecular & Medical Pharmacology (Nuclear Medicine) UCLA School of Medicine
Dr. Maddahi is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
100 Ucla Medical Plz # 410
Los Angeles, CA 90095Phone+1 310-824-4991Fax+1 310-824-7082- Is this information wrong?
Education & Training
Cedars-Sinai Medical CenterFellowship, Cardiovascular Disease, 1977 - 1981
Advocate Health Care/Advocate Illinois Masonic Medical CenterResidency, Internal Medicine, 1975 - 1977
Tehran University of Medical Sciences School of MedicineClass of 1975
Certifications & Licensure
CA State Medical License 1977 - 2024
IN State Medical License 1977 - 1978- American Board of Nuclear Medicine Nuclear Medicine
Awards, Honors, & Recognition
- Fellow (FACC) American College of Cardiology
Clinical Trials
- A Phase I Study in Healthy Volunteers to Assess Safety of BMS747158 Start of enrollment: 2007 Sep 01
- A Phase I Study in Healthy Volunteers to Assess Dosimetry and Safety Following Injection of BMS747158 at Stress Start of enrollment: 2008 Jun 01
- A Phase 3 Multi-center Study to Assess PET Imaging of Flurpiridaz F 18 Injection in Patients With CAD. Start of enrollment: 2011 Jun 01
Publications & Presentations
PubMed
- Improved myocardial blood flow estimation with residual activity correction and motion correction inF-flurpiridaz PET myocardial perfusion imaging.Yuka Otaki, Serge D Van Kriekinge, Chih-Chun Wei, Paul Kavanagh, Ananya Singh, Tejas Parekh, Marcelo Di Carli, Jamshid Maddahi, Arkadiusz Sitek, Christopher Buckley, D...> ;European Journal of Nuclear Medicine and Molecular Imaging. 2022 May 1
- 18F-flurpiridaz positron emission tomography segmental and territory myocardial blood flow metrics: incremental value beyond perfusion for coronary artery disease cate...René R Sevag Packard, John R Votaw, C David Cooke, Kenneth F Van Train, Ernest V Garcia, Jamshid Maddahi> ;European Heart Journal. Cardiovascular Imaging. 2022 Nov 17
- 3 citationsAssessing myocardial perfusion in suspected coronary artery disease: rationale and design of the second phase 3, open-label multi-center study of flurpiridaz (F-18) in...Jamieson M. Bourque, Christopher A Hanson, Denis Agostini, Timothy M. Bateman, Jeroen J. Bax, Rob S. Beanlands, Daniel S. Berman, Ernest V. Garcia, Gary V. Heller, Juh...> ;Journal of Nuclear Cardiology. 2021 Jan 31
- Join now to see all
Press Mentions
Flurpiridaz Clinical Trial Results Will Be Announced at ASNC2022August 16th, 2022- Assessing Myocardial Perfusion in Suspected Coronary Artery Disease: Rationale and Design of the Second Phase 3, Open-Label Multi-Center Study of Flurpiridaz (F-18) Injection for Positron Emission Tomography (PET) ImagingFebruary 1st, 2021
- Emerging Novel Tracers for Cardiovascular ImagingJune 17th, 2021
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
